ASCO 2026: Interim data released for upcoming BRAF and RAS mCRC therapies

Two mCRC studies, looking into patients with BRAF and RAS mutations caught the eye of experts at ASCO 2026. Two mCRC studies, looking into patients with BRAF and RAS mutations caught the eye of experts at ASCO 2026. There was data from several mCRC studies at ASCO 2026. Credit: Jo Panuwat D / Shutterstock.com Several abstracts and data presentations on emerging clinical research in metastatic colorectal cancer (mCRC) prompted expert interest and discussion at the American Society of Clinical Oncology (ASCO) 2026, held 29 May to 2 June 2026. Two of these abstracts were Cardiff Oncology’s Phase II randomised CRDF-004…

Source: Clinical Trials Arena